NRX looks great at these levelsKey Stats
Market Cap: $14.5M
52-Week Range: $1.10 - $7.33
Short Interest: 6.68%, with days to cover at 3.51
RSI (14): 41 (leaning towards oversold territory)
Technical Reasons for Upside
Price Rejection at Key Support: NRXP has been hugging the $1.20–$1.25 range, with consistent rejection a
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.079 EUR
−4.64 M EUR
0.00 EUR
59.80 M
About Nurexone Biologic Inc
Sector
Industry
CEO
Lior Shaltiel
Website
Headquarters
Toronto
Founded
2011
ISIN
CA67059R1091
FIGI
BBG00H90W3P3
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. It focuses on the treatment of spinal cord injury, traumatic brain injury, and other brain and neurological indications. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.
Related stocks
NRX - Nurexone trend analysis since bull run commencing in 2023Having a look at Nurexone trends alongside Point of Control & Ichimoku Cloud indicators. Current bullish pennant formation detected following a successful Downward Wedge.
*Next move: Trace Fibonacci retracement, indicate loss % between ATH and support levels, future projections
$NRX.V Outpaces Biotech Peers Following TSX.V Listing The biotech sector is presenting exciting opportunities for investors despite the broader downturn in global equity markets. Many of the best biotech companies and ETFs have both strong drug candidate pipelines in the works as well as winning drugs and therapeutic products already on the market. The
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Nurexone Biologic Inc stocks are traded under the ticker J90.
We've gathered analysts' opinions on Nurexone Biologic Inc future price: according to them, J90 price has a max estimate of 2.16 EUR and a min estimate of 2.16 EUR. Watch J90 chart and read a more detailed Nurexone Biologic Inc stock forecast: see what analysts think of Nurexone Biologic Inc and suggest that you do with its stocks.
Yes, you can track Nurexone Biologic Inc financials in yearly and quarterly reports right on TradingView.
Nurexone Biologic Inc is going to release the next earnings report on Nov 21, 2025. Keep track of upcoming events with our Earnings Calendar.
J90 earnings for the last quarter are −0.02 EUR per share, whereas the estimation was −0.02 EUR resulting in a −20.00% surprise. The estimated earnings for the next quarter are −0.02 EUR per share. See more details about Nurexone Biologic Inc earnings.
Nurexone Biologic Inc revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
J90 net income for the last quarter is −1.59 M EUR, while the quarter before that showed −1.55 M EUR of net income which accounts for −3.01% change. Track more Nurexone Biologic Inc financial stats to get the full picture.
No, J90 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, J90 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Nurexone Biologic Inc stock right from TradingView charts — choose your broker and connect to your account.




